[Research] LigaChem Biosciences (141080) – Eugene Investment & Securities | Pipeline Clinical Progression · Licensing Revenue · Earnings Turnaround / 2025-02-17
Brokerage : Eugene Investment & Securities Analyst : Haesun Kwon Investment Rating : BUY (Maintain) Target Price : KRW 160,000 (Maintain) Core Momentum : Sustained net profit profitability backed by rising licensing revenues alongside aggressive R&D execution and multi-pipeline clinical advancements across 2025-2026 📊 1. [Valuation & Key Financial Metrics] 🚀 2. [Market Opportunities &…